Innovationsreport 2019 Kurzfassung
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
COMMISSION DE LA TRANSPARENCE Avis 5 Septembre 2018
COMMISSION DE LA TRANSPARENCE Avis 5 septembre 2018 Date d’examen par la Commission : 20 juin 2018 L’avis de la commission de la Transparence adopté le 11 juillet 2018 a fait l’objet d’une audition le 5 septembre 2018. letermovir PREVYMIS 240 mg, comprimés pelliculés Boîte de 28 (CIP : 34009 301 272 3 0) PREVYMIS 240 mg, solution à diluer pour perfusion Boite de 1 (CIP : 34009 301 272 5 4) PREVYMIS 480 mg, comprimés pelliculés Boîte de 28 (CIP : 34009 301 272 4 7) PREVYMIS 480 mg, solution à diluer pour perfusion Boite de 1 (CIP : 34009 301 272 6 1) Laboratoire MSD France Code ATC J05AX18 (Antiviral) Motif de l’examen Inscription Sécurité Sociale (CSS L.162-17) pour les formes comprimés uniquement Listes concernées Collectivités (CSP L.5123-2) pour l’ensemble des présentations « PREVYMIS est indiqué dans la prophylaxie de la réactivation du cytomégalovirus (CMV) et de la maladie à CMV chez les adultes séropositifs au CMV receveurs [R+] d’une greffe allogénique de cellules Indication concernée souches hématopoïétiques (GCSH). Il convient de tenir compte des recommandations officielles concernant l’utilisation appropriée des agents antiviraux. » HAS - Direction de l'Evaluation Médicale, Economique et de Santé Publique 1/18 Avis3 SMR Important Compte tenu : - de la démonstration de l’efficacité de PREVYMIS en prophylaxie de la réactivation du CMV par rapport au placebo et notamment la diminution des instaurations de traitements préemptifs exposant les patients à une toxicité hématologique ou rénale importante, - de l’absence d’impact démontré -
Subtherapeutic Posaconazole Prophylaxis in a Gastric Bypass Patient Following Hematopoietic Stem Cell Transplantation
applyparastyle “fig//caption/p[1]” parastyle “FigCapt” CASE REPORT Subtherapeutic posaconazole prophylaxis in a gastric bypass patient following hematopoietic stem cell transplantation Emily A. Highsmith, PharmD, BCCCP, Department of Pharmacy, University Purpose. A case of invasive fungal infections (IFIs) with subtherapeutic of Texas MD Anderson Cancer Center, Houston, TX, USA posaconazole prophylaxis in a gastric bypass patient following hemato- poietic stem cell transplantation (HSCT) is reported. Downloaded from https://academic.oup.com/ajhp/article/78/14/1282/6245082 by BINASSS user on 15 July 2021 Vi P. Doan, PharmD, BCOP, Department of Pharmacy, University of Texas MD Anderson Cancer Center, Summary. A 52-year-old malnourished male with a medical history of Houston, TX, USA Roux-en-Y gastric bypass for obesity developed acute myelogenous leu- Todd W. Canada, PharmD, BCNSP, kemia and underwent allogeneic HSCT approximately 17 months later. He BCCCP, FASHP, FTSHP, FASPEN, was admitted 1 month after HSCT for failure to thrive and initiated on par- Department of Pharmacy, University of Texas MD Anderson Cancer Center, enteral nutrition due to worsening diarrhea and suspected gastrointestinal Houston, TX, USA graft-versus-host disease (GI GVHD). During admission, the patient was continued on daily oral posaconazole for antifungal prophylaxis and was found to have subtherapeutic posaconazole and deficient vitamin levels, likely secondary to his gastrojejunostomy and increased gastric transit time. The oral posaconazole was altered to twice-daily dosing in an effort to increase serum drug levels and prevent IFIs. Conclusion. Patients with a history of gastric bypass are at increased risk for malabsorption of oral posaconazole and nutrients, especially following HSCT with suspected GI GVHD. -
R&D Briefing 76
The Impact of Recent Regulatory Developments on the Mexican Therapeutic Landscape Access to innovative medicines is key to El acceso a medicamentos innovadores es clave para improving overall population health, reducing mejorar la salud de toda la población, para reducir los hospitalisation time and decreasing morbidity and tiempos de hospitalización, la morbilidad y la mortalidad mortality. An efficient regulatory process can be de un país. Un proceso regulatorio eficiente tiene un reflected in measurable positive health impacts; impacto positivo medible en la salud, y por el contrario, conversely, activities that slow or impede acciones que retrasan o impiden la eficiencia regulatoria y regulatory efficiency and predictability can be su predictibilidad pueden ser perjudiciales. La parálisis detrimental. Recent developments in the Mexican reciente del Sistema regulatorio mexicano respecto a la regulatory system for the assessments of evaluación de nuevos medicamentos innovadores innovative new products have had a negative conlleva un impacto negativo en la salud de la población impact on Mexican public health. mexicana. This Briefing addresses the impact of suspending Este informe analiza el impacto de la suspensión de las the activities of the New Molecules Committee actividades del Comité de Moléculas Nuevas (NMC, por (NMC) on the Mexican therapeutic landscape. sus siglas en inglés) sobre el horizonte terapéutico de First, we compared the way that “new medicines” México. En primer lugar, comparamos la definición de are defined within the context of the Mexican nuevos medicamentos según el contexto regulatorio regulatory system, with definitions used by mexicano con las definiciones adoptadas por otras comparable regulators and health organisations. agencias reguladoras u organizaciones de salud del We have also investigated the extent to which mundo. -
11-2018 BMT Pharmacists Johnson FINAL 2 12 18
2018 BMT Pharmacists Conference Infection Prophylaxis in the HCT patient Melissa D. Johnson, PharmD, AAHIVP Associate Professor of Medicine Duke University Medical Center Liaison Clinical Pharmacist Duke Antimicrobial Stewardship Outreach Network Durham, North Carolina [email protected] @idpharmacist Disclosures • Research grants: Merck, Charles River Laboratories Objectives • Assess the factors influencing risk of infection in hematopoietic cell transplant recipients • Compare and contrast current, recently approved and emerging antimicrobials for prophylaxis in hematopoietic cell transplant recipients • Discuss recent studies evaluating antimicrobials for prophylaxis in hematopoietic cell transplant recipients • Identify important monitoring parameters and supportive strategies for prophylaxis in hematopoietic cell transplant recipients Hematopoietic Cell Transplantation Transplant Variables and Infection Risk • Underlying disease Pre-Tx Stem cells • Type of transplant Therapy +/- GVHD Autologous, Allogeneic • HLA matching Conditioning • Conditioning regimen Engraftment • Source of stem cells • Graft manipulation • Graft versus host disease • Donor & recipient age Bacterial Viruses Fungal INFECTIOUS PATHOGENS Respiratory Pneumocystis Viruses Other Case Question 1 • 37-year-old male with AML Initial presentation: • 45,000 WBC, normal cytogenetics, FLT3/ITD genes (+), NPM1 (-) Treatment plan: Standard induction followed by allogeneic hematopoietic peripheral blood stem-cell transplant • Which of the following pathogens is he at greatest -
Suomen Lääketilasto 2019
SUOMEN LÄÄKETILASTO S LT FINNISH STATISTICS ON MEDICINES FSM 2019 Keskeisiä lukuja lääkkeiden myynnistä ja lääkekorvauksista vuonna 2019 Milj. € Muutos vuodesta 2018, % Lääkkeiden kokonaismyynti 3 460 5,2 avohoidon reseptilääkkeiden myynti (verollisin vähittäismyyntihinnoin) 2 284 4,4 avohoidon itsehoitolääkkeiden myynti (verollisin vähittäismyyntihinnoin) 357 0,8 sairaalamyynti (tukkuohjehinnoin) 818 9,9 Lääkkeistä maksetut korvaukset 1 551 6,2 peruskorvaukset 316 3,0 erityiskorvaukset 1 029 5,2 lisäkorvaukset 205 17,7 Key figures for medicine sales and their reimburssement in 2019 € million Change from 2018, % Total sales of pharmaceuticals 3,460 5.2 prescription medicines in outpatient care (at pharmacy prices with VAT) 2,284 4.4 OTC medicines in outpatient care (at pharmacy prices with VAT) 357 0.8 sales to hospitals (at wholesale prices) 818 9.9 Reimbursement of medicine costs 1,551 6.2 Basic Refunds 316 3.0 Special Refunds 1,029 5.2 Additional Refunds 205 17.7 Lähde: Fimean lääkemyyntirekisteri, Kelan sairausvakuutuskorvausten tilastointitiedosto. Source: Finnish Medicines Agency, Drug Sales Register; Register of Statistical Information on National Health Insurance General Benefit Payments. SUOMEN LÄÄKETILASTO FINNISH STATISTICS ON MEDICINES 2019 Lääkealan turvallisuus- ja kehittämiskeskus Fimea ja Kansaneläkelaitos Finnish Medicines Agency Fimea and Social Insurance Institution Helsinki 2020 LÄÄKEALAN TURVALLISUUS- KANSANELÄKELAITOS JA KEHITTÄMISKESKUS FIMEA FINNISH MEDICINES AGENCY FIMEA SOCIAL INSURANCE INSTITUTION Lääketurvallisuus Analytiikka- ja tilastoryhmä Pharmacovigilance Section for Analytics and Statistics Mannerheimintie 166 Nordenskiöldinkatu 12 P.O. Box 55 P.O. Box 450 FI-00034 Fimea FI-00056 Kela Finland Finland [email protected] [email protected] Puh. 029 522 3341 Puh. 020 634 11 Tel. +358 29 522 3341 Tel. -
Kongressjournal Wmw Wiener Medizinische Wochenschrift
W Band 8 / Heft 10 www.springer.at/wmw-skriptum ISSN Print 1613-3803 P. b. b. Verlagspostamt 1201 Wien Plus.Zeitung 07Z037513P SpringerMedizin.at/schwerpunkt/oegari-2011 10/11 skriptum Kongressjournal wmw Wiener Medizinische Wochenschrift 15. bis 17. September 2011, Wien Jahrestagung der Österreichischen Gesellschaft für Anästhesiologie, Reanimation und Intensivmedizin Austrian International Congress 2011 – AIC Wissenschaftliche Leitung: Prim. Univ.-Prof. Dr. Sibylle Kozek-Langenecker inhalt 10/11 Inhalt brief der herausgeberin Jahrestagung der 4 Willkommen in Wien! Österreichischen S. Kozek-Langenecker Gesellschaft für beiträge Anästhesiologie, 6 Sedierung durch Nicht-AnästhesistInnen Reanimation und Robert D. Fitzgerald, Wien Intensivmedizin 7 Gerinnungsmanagement bei traumatisch bedingter (ÖGARI) Massivblutung D. Fries, P. Innerhofer, P. Perger, M. Gütl, S. Heil, N. Hofmann, W. Kneifl, L. 15. bis 17. September Neuner, T. Pernerstorfer, G. Pfanner, H. Schöchl, B. Ziegler, C. Köblinger und 2011, Wien S. Kozek-Langenecker, ARGE für perioperative Gerinnung der ÖGARI 10 Erstversorgung von SHT W. Mauritz und A. Brazinova, Wien 11 Extrakorporaler Gasaustausch W. Oczenski und C. Hörmann, Wien–St. Pölten 16 „Coagulation Day 2010“: Thrombosemanagement beim kritisch Kranken E. Schaden, Wien 19 Koma: Differenzialdiagnose im Notfall Schloss Schönbrunn E. Schmutzhard, Innsbruck 20 Präklinische Intubation A. von Goedecke, Steyr 21 Perioperative Gerinnungsoptimierung P. Innerhofer, D. Fries und M. Mittermayr, Innsbruck 24 Ist Muskelrelaxation noch zeitgemäß? K. Khünl-Brady, Innsbruck 26 Impressum wmw skriptum © Springer-Verlag 10/2011 3 brief der herausgeberin Willkommen in Wien! Sehr geehrte Kolleginnen, sehr geehrte Kollegen! Kurzfristig wurde uns die Möglichkeit eröffnet, Beiträge vom diesjährigen Kongress der Österreichi- schen Gesellschaft für Anästhesiologie, Reanimation und Intensivmedizin (ÖGARI) mit diesem PRIM. -
Hinge Region in DNA Packaging Terminase Pul15 of Herpes Simplex Virus: a Potential Allosteric Target for Antiviral Drugs
Louisiana State University LSU Digital Commons Faculty Publications School of Renewable Natural Resources 10-1-2019 Hinge Region in DNA Packaging Terminase pUL15 of Herpes Simplex Virus: A Potential Allosteric Target for Antiviral Drugs Lana F. Thaljeh Louisiana State Univ, Dept Biol Sci, [email protected] J. Ainsley Rothschild Louisiana State Univ, Div Elect & Comp Engn, [email protected] Misagh Naderi Louisiana State Univ, Dept Biol Sci, [email protected] Lyndon M. Coghill Louisiana State Univ, Dept Biol Sci, [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/agrnr_pubs Part of the Biology Commons Recommended Citation Thaljeh, Lana F.; Rothschild, J. Ainsley; Naderi, Misagh; and Coghill, Lyndon M., "Hinge Region in DNA Packaging Terminase pUL15 of Herpes Simplex Virus: A Potential Allosteric Target for Antiviral Drugs" (2019). Faculty Publications. 4. https://digitalcommons.lsu.edu/agrnr_pubs/4 This Article is brought to you for free and open access by the School of Renewable Natural Resources at LSU Digital Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital Commons. For more information, please contact [email protected]. biomolecules Article Hinge Region in DNA Packaging Terminase pUL15 of Herpes Simplex Virus: A Potential Allosteric Target for Antiviral Drugs Lana F. Thaljeh 1, J. Ainsley Rothschild 1, Misagh Naderi 1, Lyndon M. Coghill 1,2 , Jeremy M. Brown 1 and Michal Brylinski 1,2,* 1 Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA; [email protected] (L.F.T.); [email protected] (J.A.R.); [email protected] (M.N.); [email protected] (L.M.C.); [email protected] (J.M.B.) 2 Center for Computation & Technology, Louisiana State University, Baton Rouge, LA 70803, USA * Correspondence: [email protected]; Tel.: +225-578-2791; Fax: +225-578-2597 Received: 10 September 2019; Accepted: 8 October 2019; Published: 12 October 2019 Abstract: Approximately 80% of adults are infected with a member of the herpesviridae family. -
Where Do We Stand After Decades of Studying Human Cytomegalovirus?
microorganisms Review Where do we Stand after Decades of Studying Human Cytomegalovirus? 1, 2, 1 1 Francesca Gugliesi y, Alessandra Coscia y, Gloria Griffante , Ganna Galitska , Selina Pasquero 1, Camilla Albano 1 and Matteo Biolatti 1,* 1 Laboratory of Pathogenesis of Viral Infections, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy; [email protected] (F.G.); gloria.griff[email protected] (G.G.); [email protected] (G.G.); [email protected] (S.P.); [email protected] (C.A.) 2 Complex Structure Neonatology Unit, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy; [email protected] * Correspondence: [email protected] These authors contributed equally to this work. y Received: 19 March 2020; Accepted: 5 May 2020; Published: 8 May 2020 Abstract: Human cytomegalovirus (HCMV), a linear double-stranded DNA betaherpesvirus belonging to the family of Herpesviridae, is characterized by widespread seroprevalence, ranging between 56% and 94%, strictly dependent on the socioeconomic background of the country being considered. Typically, HCMV causes asymptomatic infection in the immunocompetent population, while in immunocompromised individuals or when transmitted vertically from the mother to the fetus it leads to systemic disease with severe complications and high mortality rate. Following primary infection, HCMV establishes a state of latency primarily in myeloid cells, from which it can be reactivated by various inflammatory stimuli. Several studies have shown that HCMV, despite being a DNA virus, is highly prone to genetic variability that strongly influences its replication and dissemination rates as well as cellular tropism. In this scenario, the few currently available drugs for the treatment of HCMV infections are characterized by high toxicity, poor oral bioavailability, and emerging resistance. -
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems. -
List of Drugs Not Repackaged by Safecor Health
Drugs Not Repackaged by Safecor Health The following tables list specific medications that are not repackaged by Safecor Health due to regulatory restrictions or specific manufacturer requirements. The items not repackaged are alphabetically listed below, both by brand name (table 1) and generic name (table 2). Please note: Safecor Health cannot repackage any beta lactam antibiotics (such as penicillins, amoxicillin and cephalosporins) or potent chemotherapeutic agents. Also, due to FDA restrictions, we cannot repackage half- or quarter-tabs, compounded or diluted drugs, powders, and ointments or creams. Safecor Health can repackage most hazardous drugs on the NIOSH list. Contact us for a complete list of hazardous drugs repackaged by Safecor Health. Table 1. Do Not Repackage Drugs Sorted Alphabetically by Brand Name Brand Name(s) Generic Name(s) Reason Item Cannot Be Repackaged Adrucil Fluorouracil Potent chemotherapy agent Aspirin and Extended-Release Specific manufacturer recommendations for very Aggrenox Dipyridamole limited expiration dating Albenza Albendazole Cost per dose prohibitive Alkeran Melphalan Potent chemotherapy agent Augmentin Amoxicillin and Clavulanate Potassium Safecor Health does not repackage this drug class Manufacturer states, "dispense in original container," Belsomra Suvorexant on the drug label Manufacturer states, "dispense in original container," Biktarvy Bictegravir, Emtricitabine and Tenofovir Alafenamide on the drug label Bion Tears Dextran, Hypromellose Ophthalmic Drops Sterile and unpreserved CeeNU Lomustine -
Human Cytomegalovirus Primary Infection and Reactivation: Insights from Virion-Carried Molecules
fmicb-11-01511 July 16, 2020 Time: 8:16 # 1 REVIEW published: 14 July 2020 doi: 10.3389/fmicb.2020.01511 Human Cytomegalovirus Primary Infection and Reactivation: Insights From Virion-Carried Molecules Yu-Qing Wang1,2 and Xiang-Yu Zhao1* 1 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, 2 PKU-THU Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China Human cytomegalovirus (HCMV), a ubiquitous beta-herpesvirus, is able to establish lifelong latency after initial infection. Periodical reactivation occurs after immunosuppression, remaining a major cause of death in immunocompromised patients. HCMV has to reach a structural and functional balance with the host at Edited by: its earliest entry. Virion-carried mediators are considered to play pivotal roles in viral Akio Adachi, adaptation into a new cellular environment upon entry. Additionally, one clear difference Kansai Medical University, Japan between primary infection and reactivation is the idea that virion-packaged factors are Reviewed by: Eain Anthony Murphy, already formed such that those molecules can be used swiftly by the virus. In contrast, SUNY Upstate Medical University, virion-carried mediators have to be transcribed and translated; thus, they are not readily United States Sarah Elizabeth Jackson, available during reactivation. Hence, understanding virion-carried -
BMJ Paediatrics Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
bmjpo: first published as 10.1136/bmjpo-2020-000880 on 30 December 2020. Downloaded from BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay- per-view fees (http://bmjpaedsopen.bmj.com). If you have any questions on BMJ Paediatrics Open’s open peer review process please email [email protected] http://bmjpaedsopen.bmj.com/ on September 25, 2021 by guest. Protected copyright. BMJ Paediatrics Open bmjpo: first published as 10.1136/bmjpo-2020-000880 on 30 December 2020. Downloaded from Confidential: For Review Only Does the EU’s Paediatric Regulation work for new medicines for children in Nordic countries? A retrospective database review. Journal: BMJ Paediatrics Open Manuscript ID bmjpo-2020-000880 Article Type: Original research Date Submitted by the 16-Sep-2020 Author: Complete List of Authors: Lepola , Pirkko ; Helsinki University Central Hospital, Children and Adolescents Wang, Siri; Norwegian Medicines Agency Tötterman, Ann Marie; Finnish Medicines Agency Fimea Gullberg, Ninna; Swedish Medicinal products Agency Moll Harboe, Kirstine ; Danish Medicines Agency Kimland, Elin; Swedish Medicinal Products Agency Keywords: Therapeutics, Pharmacology http://bmjpaedsopen.bmj.com/ on September 25, 2021 by guest.